» Articles » PMID: 26287961

A Longitudinal Study of Growth, Sex Steroids, and IGF-1 in Boys With Physiological Gynecomastia

Overview
Specialty Endocrinology
Date 2015 Aug 20
PMID 26287961
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Physiological gynecomastia is common and affects a large proportion of otherwise healthy adolescent boys. It is thought to be caused by an imbalance between estrogen and testosterone, although this is rarely evident in analyses of serum.

Objective: This study aimed to describe the frequency of physiological gynecomastia and to determine possible etiological factors (eg, auxology and serum hormone levels) in a longitudinal setup.

Design, Settings, And Participants: A prospective cohort study of 106 healthy Danish boys (5.8-16.4 years) participated in the longitudinal part of the COPENHAGEN Puberty Study. The boys were examined every 6 months during an 8-year follow-up. Median number of examinations was 10 (2-15).

Main Outcome Measurements: Blood samples were analyzed for FSH, LH, testosterone, estradiol, SHBG, inhibin B, anti-Müllerian hormone, IGF-1, and IGF binding protein-3 by immunoassays. Auxological parameters, pubertal development, and the presence of gynecomastia were evaluated at each visit.

Results: Fifty-two of 106 boys (49%) developed gynecomastia, of which 10 (19%) presented with intermittent gynecomastia. Boys with physiological gynecomastia reached peak height velocity at a significantly younger age than boys who did not develop gynecomastia (13.5 versus 13.9 years, P = .027), and they had significantly higher serum levels of IGF-1 (P = .000), estradiol (P = .013), free testosterone (P < .001), and FSH (P = .030) during pubertal transition. However, no differences in serum LH or in the estradiol to testosterone ratio were found.

Conclusions: Gynecomastia is frequent in pubertal boys. Increased IGF-1 levels and pubertal growth appear to be associated, whereas changes in estrogen to testosterone ratio seem negligible.

Citing Articles

Deep Learning-Based Drug Compounds Discovery for Gynecomastia.

Lu Y, Kim B, Zeng J, Chen Z, Zhu M, Tang Y Biomedicines. 2025; 13(2).

PMID: 40002676 PMC: 11852009. DOI: 10.3390/biomedicines13020262.


Endocrine Hormones and Their Impact on Pubertal Gynecomastia.

Shi Z, Xin M J Clin Med. 2025; 14(1.

PMID: 39797240 PMC: 11721017. DOI: 10.3390/jcm14010158.


"Management of andrological disorders from childhood and adolescence to transition age: guidelines from the Italian Society of Andrology and Sexual Medicine (SIAMS) in collaboration with the Italian Society for Pediatric Endocrinology and....

Bonomi M, Cangiano B, Cianfarani S, Garolla A, Gianfrilli D, Lanfranco F J Endocrinol Invest. 2024; 48(1):1-22.

PMID: 39126560 PMC: 11729124. DOI: 10.1007/s40618-024-02435-x.


MKRN3 circulating levels in girls with central precocious puberty caused by MKRN3 gene mutations.

Aiello F, Palumbo S, Cirillo G, Tornese G, Fava D, Wasniewska M J Endocrinol Invest. 2023; 47(6):1477-1485.

PMID: 38112911 DOI: 10.1007/s40618-023-02255-5.


[Prepubertal gynecomastia at the debut of hereditary tumors predisposition syndrome (clinical case reports)].

Kareva M, Sozaeva L, Chugunov I, Peterkova V, Mikhalina S Probl Endokrinol (Mosk). 2023; 69(4):101-106.

PMID: 37694873 PMC: 10520907. DOI: 10.14341/probl13239.